- Home
- EOD vs ESPR Comparison
EOD vs ESPR Comparison
Compare EOD & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOD
- ESPR
- Stock Information
- Founded
- EOD 2007
- ESPR 2008
- Country
- EOD United States
- ESPR United States
- Employees
- EOD N/A
- ESPR N/A
- Industry
- EOD Investment Managers
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- EOD Finance
- ESPR Health Care
- Exchange
- EOD Nasdaq
- ESPR Nasdaq
- Market Cap
- EOD 239.9M
- ESPR 220.0M
- IPO Year
- EOD N/A
- ESPR 2013
- Fundamental
- Price
- EOD $5.67
- ESPR $2.17
- Analyst Decision
- EOD
- ESPR Buy
- Analyst Count
- EOD 0
- ESPR 6
- Target Price
- EOD N/A
- ESPR $6.50
- AVG Volume (30 Days)
- EOD 118.1K
- ESPR 5.2M
- Earning Date
- EOD 01-01-0001
- ESPR 08-05-2025
- Dividend Yield
- EOD 9.28%
- ESPR N/A
- EPS Growth
- EOD N/A
- ESPR N/A
- EPS
- EOD N/A
- ESPR N/A
- Revenue
- EOD N/A
- ESPR $268,125,000.00
- Revenue This Year
- EOD N/A
- ESPR $6.10
- Revenue Next Year
- EOD N/A
- ESPR N/A
- P/E Ratio
- EOD N/A
- ESPR N/A
- Revenue Growth
- EOD N/A
- ESPR N/A
- 52 Week Low
- EOD $3.73
- ESPR $0.69
- 52 Week High
- EOD $4.71
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- EOD 57.69
- ESPR 73.45
- Support Level
- EOD $5.61
- ESPR $2.00
- Resistance Level
- EOD $5.77
- ESPR $2.14
- Average True Range (ATR)
- EOD 0.06
- ESPR 0.15
- MACD
- EOD -0.01
- ESPR 0.02
- Stochastic Oscillator
- EOD 57.83
- ESPR 95.08
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.